CLEVELAND, Nov. 12, 2013 /PRNewswire/ -- ChanRx, a firm developing medicines for cardiovascular diseases, today announced that it will be presenting the results of its Phase IIb study of vanoxerine (GBR-12909), a drug under study for the treatment of atrial fibrillation, at the American Heart Association 2013 Scientific Sessions conference.
The study, titled "COR-ART: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose Modification Study to Evaluate Single Oral Doses of GBR-12909 for Conversion of Subjects with Atrial Fibrillation or Flutter of Recent Onset to Normal Science Rhythm," will be presented on November 17, 2013.
ChanRx is focused on developing small molecules for cardiovascular diseases. The company was spun out from ChanTest, the world's most trusted ion channel services company with particular expertise in testing pharmaceutical compounds for cardiac safety. Its lead candidate is vanoxerine, a small molecule under development for atrial fibrillation or atrial flutter, which has demonstrated promising data in trials through Phase IIb.